Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative

References

• HardyJSelkoeDJThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience2002297558035335612130773
   PubMed Web of Science ®Google Scholar
• TrinhNHHoblynJMohantySYaffeKEfficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysisJAMA2003289221021612517232
   PubMed Web of Science ®Google Scholar
• JichaGAParisiJEDicksonDWNeuropathologic outcome of mild cognitive impairment following progression to clinical dementiaArch Neurol200663567468116682537
   PubMedGoogle Scholar
• Food and Drug AdministrationDraft Guidance for Industry: Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage DiseaseWashington, DCCenter for Drug Evaluation and Research2013
   Google Scholar
• Food and Drug AdministrationDraft Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological ProductsWashington, DCCenter for Drug Evaluation and Research2013
   Google Scholar
• CedarbaumJMJarosMHernandezCAlzheimer’s Disease Neuroimaging InitiativeRationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trialsAlzheimers Dement20139Suppl 1S45S5522658286
   PubMed Web of Science ®Google Scholar
• WilliamsMMStorandtMRoeCMMorrisJCProgression of Alzheimer’s disease as measured by Clinical Dementia Rating Sum of Boxes scoresAlzheimers Dement20139Suppl 1S39S4422858530
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyQualification Opinion of a Novel Data Driven Model of Disease Progression and Trial Evaluation in Mild and Moderate Alzheimer’s DiseaseLondonEuropean Medicines Agency2013
   Google Scholar
• RomeroKStephensonDRogersJAdvancement of a drug-disease trial model for Alzheimer’s disease through a regulatory science path: The CAMD experienceAlzheimers Dement201284P587P588
   Google Scholar
• RogersJAPolhamusDGillespieWRCombining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a β regression meta-analysisJ Pharmacokinet Pharmacodyn201239547949822821139
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyQualification Opinion òf Low Hippocampal Volume (Atrophy) by MRI for Use in Clinical Trials for Regulatory Purpose – in Pre-Dementia Stage Of Alzheimer’s DiseaseLondonEuropean Medicines Agency2011 Available from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2011/12/WC500118737.pdfAccessed April 4, 2014
   Google Scholar
• European Medicines AgencyQualification Opinion of Alzheimer’s Disease Novel Methodologies/Biomarkers for BMS-708163LondonEuropean Medicines Agency2011
   Google Scholar
• European Medicines AgencyQualification Opinion of Alzheimer’s Disease Novel Methodologies/Biomarkers for PET Amyloid Imaging (Positive/Negative) as a Biomarker for Enrichment for Use – in Predementia AD Clinical TrialsLondonEuropean Medicines Agency2011
   Google Scholar
• JagustWJLandauSMShawLMAlzheimer’s Disease Neuroimaging InitiativeRelationships between biomarkers in aging and dementiaNeurology200973151193119919822868
   PubMed Web of Science ®Google Scholar
• LiuYMattilaJRuizMÁAlzheimer’s Disease Neuroimaging InitiativePredicting AD conversion: comparison between prodromal AD guidelines and computer assisted Predict AD toolPLoS One201382e5524623424625
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease Cooperative Study (ADCS)ADNI: Alzheimer’s Disease Neuroimaging InitiativeClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 [updated May 15, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT00106899. NLM identifier: NCT00106899Accessed March 26, 2014
   Google Scholar
• ADNI data training part 2ADNI biostatistics core team812013 Available from http://adni.loni.usc.edu/wp-content/uploads/2012/08/slide_data_training_part2_reduced-size.pdfAccessed April 4, 2014
   Google Scholar
• BealSLSheinerLBBoeckmannAJBauerRJNONMEM 7.2.0 Users GuideEllicott City, MDIcon Development Solutions19892011
   Google Scholar
• LindbomLPihlgrenPJonssonENJonssonNPsN-Toolkit – a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComput Methods Programs Biomed200579324125716023764
   PubMed Web of Science ®Google Scholar
• ItoKCorriganBZhaoQAlzheimer’s Disease Neuroimaging InitiativeDisease progression model for cognitive deterioration from Alzheimer’s Disease Neuroimaging Initiative databaseAlzheimers Dement20117215116020810324
   PubMed Web of Science ®Google Scholar
• ItoKHutmacherMMCorriganBWModeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI databaseJ Pharmacokinet Pharmacodyn201239660161822990808
   PubMed Web of Science ®Google Scholar
• William-FaltaosDChenYWangYGobburuJZhuHQuantification of disease progression and dropout for Alzheimer’s diseaseInt J Clin Pharmacol Ther201351212013123211395
   PubMed Web of Science ®Google Scholar
• TsoularisAWallaceJAnalysis of logistic growth modelsMath Biosci20021791215512047920
   PubMed Web of Science ®Google Scholar
• SamtaniMNFarnumMLobanovVAlzheimer’s Disease Neuroimaging InitiativeAn improved model for disease progression in patients from the Alzheimer’s disease neuroimaging initiativeJ Clin Pharmacol201252562964421659625
   PubMed Web of Science ®Google Scholar
• SamtaniMNRaghavanNShiYAlzheimer’s Disease Neuroimaging InitiativeDisease progression model in subjects with mild cognitive impairment from the Alzheimer’s disease neuroimaging initiative: CSF biomarkers predict population subtypesBr J Clin Pharmacol201375114616122534009
   PubMed Web of Science ®Google Scholar
• AshfordJWSchmittFAModeling the time-course of Alzheimer dementiaCurr Psychiatry Rep200131202811177755
   PubMedGoogle Scholar
• XuXSSamtaniMNDunneANandyPVermeulenADe RidderFAlzheimer’s Disease Neuroimaging InitiativeMixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundariesJ Pharmacokinet Pharmacodyn201340453754423645382
   PubMed Web of Science ®Google Scholar
• BurnhamKPAndersonDRModel Selection and Multimodel Inference: A Practical Information-Theoretic Approach2nd edNew York, NYSpringer2002
   Google Scholar
• FredericPLadFTwo moments of the logitnormal distributionCommun Stat Simul Comput200837712631269
   Web of Science ®Google Scholar
• SmithsonMVerkuilenJA better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variablesPsychol Methods2006111547116594767
   PubMed Web of Science ®Google Scholar
• VerkuilenJSmithsonMMixed and mixture regression models for continuous bounded responses using the beta distributionJ Educ Behav Stat201237182113
   Web of Science ®Google Scholar
• JackCRTwomeyCKZinsmeisterARSharbroughFWPetersenRCCascinoGDAnterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adultsRadiology198917225495542748838
   PubMed Web of Science ®Google Scholar
• SiddiquiOHungHMO’NeillRMMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasetsJ Biopharm Stat200919222724619212876
   PubMed Web of Science ®Google Scholar
• KleinbaumDGKleinMSurvival Analysis. A Self-Learning Text2nd edNew York, NYSpringer2005
   Google Scholar
• FribergLEde GreefRKerbuschTKarlssonMOModeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophreniaClin Pharmacol Ther2009861849119387434
   PubMed Web of Science ®Google Scholar
• PetersenRCAisenPSBeckettLAAlzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterizationNeurology201074320120920042704
   PubMed Web of Science ®Google Scholar
• MagerDEWyskaEJuskoWJDiversity of mechanism-based pharmacodynamic modelsDrug Metab Dispos200331551051812695336
   PubMed Web of Science ®Google Scholar
• JanssenResearchDevelopmentLLCA study to evaluate the effects of JNJ-54861911 on amyloid beta processing in cerebrospinal fluid and plasma in patients with prodromal Alzheimer’s disease Available from: http://clinicaltrials.gov/ct2/show/NCT01978548?term=CSFAβ1-42&rank=2. NLM identifier: NCT01978548Accessed December 1, 2013
   Google Scholar
• Merck Sharp and Dohme CorpEfficacy and safety trial of MK-8931 in participants with prodromal Alzheimer’s disease (MK-8931-019) (APECS) Available from: http://clinicaltrials.gov/ct2/show/NCT01953601?term=abetaMK&rank=3. NLM identifier: NCT01953601Accessed December 1, 2013
   Google Scholar
• Bristol-Myers SquibbA multicenter, double blind, placebo-controlled, safety and tolerability study of BMS-708163 in patients with prodromal Alzheimer’s disease Available from: http://clinicaltrials.gov/ct2/show/NCT00890890?term=BMS-708163&rank=8. NLM identifier: NCT00890890Accessed December 1, 2013
   Google Scholar
• TondelliMWilcockGKNichelliPDe JagerCAJenkinsonMZamboniGStructural MRI changes detectable up to ten years before clinical Alzheimer’s diseaseNeurobiol Aging2012334825.e25e825.e3621782287
   PubMed Web of Science ®Google Scholar
• JackCRKnopmanDSJagustWJTracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkersLancet Neurol201312220721623332364
   PubMed Web of Science ®Google Scholar
• LandauSMHarveyDMadisonCMAlzheimer’s Disease Neuroimaging InitiativeComparing predictors of conversion and decline in mild cognitive impairmentNeurology201075323023820592257
   PubMed Web of Science ®Google Scholar